Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Research Grant System Expands in Japan For Academics Hungry For Industry Collaborations

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Unlike the handful of global pharmaceutical competitors that closed up research operations in Japan a few years ago, AstraZeneca PLC has never had research facilities in Japan to close. But now, the company is trying to tap into academia to find useful technologies by awarding small grants to researchers, a program so successful that the company has launched similar efforts in South Korea and Russia
Advertisement

Related Content

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
AZ Continues To Buy Pipeline With $100M Rigel Deal
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC079053

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel